Final Report: Primary Outcome

U01 registered as NCT02938377

Primary Analyst: Robin Nance

The estimate of pre-post intervention on AUDIT-C score was estimated in a pre/post quasi-experimental design with a linear mixed model with a term for time of intervention, clustered by patient, exchangeable covariance matrix, and robust confidence intervals. The study period was restricted to measures within 18 months of treatment initiation. All eligible participants were included, even when there were not measurements both before and after treatment. There were 142 participants in the final analysis which is based on 495 AUDIT-C measurements.

AUDIT-C score is -1.2 points post intervention, 95% Robust Confidence Interval (-1.6,-0.8).

Interpretation: AUDIT-C scores had a small but statistically significant [p<0.001] drop post intervention.

Demographics of 142 participants overall and by arm

	Prime	Pharma	Overall
N	115	27	142
Age Mean (SD)	48 (12)	45 (11)	47 (12)
Age Median [IQR]	49 [38,57]	48 [39,54]	49 [38,56]
Race/ethnicity			
Non-Hispanic White	45 (39%)	9 (33%)	54 (38%)
Non-Hispanic Black	55 (48%)	8 (30%)	63 (44%)
Hispanic	11 (10%)	9 (33%)	20 (14%)
Other	4 (3%)	1 (4%)	5 (4%)
Sex			
Female	22 (19%)	3 (11%)	25 (18%)
Male	93 (81%)	24 (89%)	117 (82%)
Site			
UW (Washington)	24 (21%)	1 (4%)	25 (18%)
JH (Maryland)	23 (20%)	2 (7%)	25 (18%)
UAB (Alabama)	40 (35%)	5 (19%)	45 (32%)
UCSD (California)	28 (24%)	19 (70%)	47 (33%)